Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02675400 · ClinicalTrials.gov registry record · Phase 4
Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)
A Phase 4 study, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT02675400 is a Phase 4 study that has completed, run by Seattle Children's Hospital. The registered enrollment target is 19 participants.
The verdict
NCT02675400, a Phase 4 study, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
In contrast to mothers with Attention Deficit/Hyperactivity Disorder (ADHD), the impact of paternal ADHD in families and children with ADHD symptoms has not been studied, despite the prevalence of ADHD in males. Thus, the investigators do not know the feasibility, impact on treatment on the family and child, and effects of treating fathers relative to mothers with ADHD. Paternal ADHD is associated with negative parenting and child conduct problems. The investigators hypothesize that successfully treating parental ADHD in fathers will have a beneficial effects on the family that will extend to the child. Specifically, the investigators believe that stimulant medication ((Lisdexamfetamine (LDX) or a different ADHD medication if poor response to LDX) with fathers will reduce father's ADHD symptoms and improve parenting. Effects of stimulant treatment of fathers will be compared to Behavioral Parent Training (BPT) on parenting, and paternal and child outcomes in fathers with ADHD who have children between the ages of 3 -8. As in the investigator's previous work, the investigators will bank paternal and child DNA and RNA for later examination of pharmacogenetic and epigenetic effects (i.e. RNA) of stimulant response.
Interventions
- DRUG Methylphenidate
- BEHAVIORAL Behavioral Parent Training
- DRUG Vyvanse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02675400
The ClinicalTrials.gov registry entry for NCT02675400 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Methylphenidate is the first listed.
NCT02675400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02675400 about?
NCT02675400 is a clinical study titled "Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)". In contrast to mothers with Attention Deficit/Hyperactivity Disorder (ADHD), the impact of paternal ADHD in families and children with ADHD symptoms has not been studied, despite the prevalence of ADHD in males. Thus, the investigators do not know the feasibility, impact on treatment on the family a...
What is the current status of trial NCT02675400?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2015-12. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT02675400?
The interventions under investigation include: Methylphenidate (DRUG), Behavioral Parent Training (BEHAVIORAL), Vyvanse (DRUG).
Who is sponsoring clinical trial NCT02675400?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.